THERAPYX INC.

TherapyX is at the forefront of innovative medical solutions, specializing in the development of advanced biologic therapies aimed at treating a variety of serious health conditions, including cancer, infectious diseases, and autoimmune disorders. Utilizing a groundbreaking technology, TherapyX encapsulates large biological molecules into an orally ingestible format, ensuring they remain intact as they are transported to the affected tissues. This unique approach allows for effective parenteral, oral, and mucosal delivery of microparticulate protein therapeutics, providing patients with cutting-edge treatment options that enhance the efficacy of traditional therapies. The clinic's commitment to advancing healthcare is reflected in its strategic partnerships with leading oncologists and research institutions, such as the University of Rochester and Intravacc. These collaborations have led to significant developments, including the EXStaM PCX12™ for pancreatic cancer and GneX12™, which aims to be the first therapeutic and prophylactic vaccine for gonorrhea. Furthermore, TherapyX's innovative immune therapy for Familial Adenomatous Polyposis has recently received FDA Orphan Drug Designation, underscoring the clinic's focus on addressing unmet medical needs. With a strong emphasis on protecting its intellectual property and continuously pushing the boundaries of pharmaceutical research, TherapyX is poised to change the landscape of medicine and improve patient outcomes.